


SCH772984

## Chemical Properties

CAS No. :	942183-80-4
Formula:	C33H33N9O2
Molecular Weight:	587.67
Storage:	Store at low temperature Powder: -20°C for 3 years   In solvent: -80°C for 1 year <small>Actual storage temperature shall be subject to the COA.</small>



## Biological Description

Description	SCH772984 is an ERK inhibitor that inhibits ERK1 and ERK2 (IC50=4/1 nM) and is highly selective and ATP-competitive. SCH772984 exhibits antitumor activity against BRAF or RAS mutant cells.
Targets(IC50)	ERK,MEK
In vitro	<p><b>METHODS:</b> Twenty-one melanoma cell lines containing mutations in the BRAF gene were treated with SCH772984 (0-10 <math>\mu</math>M) for 72-120 h. Cell viability was measured by CellTiter-Glo Luminescent Cell Viability Assay.</p> <p><b>RESULTS:</b> Among 21 cell lines, sensitivity to SCH-772984 was categorized into 3 groups: highly sensitive (IC50 1 <math>\mu</math>M), moderately sensitive (IC50= 1-2 <math>\mu</math>M) and resistant (IC50&gt; 2 <math>\mu</math>M). [1]</p> <p><b>METHODS:</b> BRAF mutant A375 cells were treated with SCH772984 (0.1-2 <math>\mu</math>mol/L) for 4 h, and the expression levels of target proteins were detected by Western Blot.</p> <p><b>RESULTS:</b> Epirubicin significantly increased sub-G cells in G2/M block. [2]</p>
In vivo	<p><b>METHODS:</b> To detect anti-tumor activity in vivo, SCH772984 (25-50 mg/kg) was administered intraperitoneally to Nude mice bearing MiaPaCa xenografts twice daily for 14 days.</p> <p><b>RESULTS:</b> Tumor regression was observed at both doses, 9% at the 25 mg/kg dose and 36% at the 50 mg/kg dose. [2]</p>
Kinase Assay	SCH772984 was tested in 8-point dilution curves in duplicate against purified ERK1 or ERK2. The enzyme was added to the reaction plate and incubated with the compound before adding a solution of substrate peptide and ATP. Fourteen microliters of diluted enzyme (0.3 ng active ERK2 per reaction) was added to each well of a 384-well plate. The plates were gently shaken to mix the reagents and incubated for 45 minutes at room temperature. The reaction was stopped with 60 $\mu$ L of IMAP Binding Solution (1: 2,200 dilutions of IMAP beads in 1 $\times$ binding buffer). The plates were incubated at room temperature for an additional 0.5 hours to allow complete binding of phosphopeptides to the IMAP beads. Plates were read on the LJL Analyst [1].
Cell Research	For resistant cell line creation, cells were grown in Dulbecco's modified Eagle medium with 10% heat-inactivated FBS media and increasing concentrations of inhibitor (PLX4032, 0.1-10 $\mu$ mol/L; GSK1120212, 0.01-1 $\mu$ mol/L) over approximately 4 to 8 months until resistant cells acquired growth properties similar to naive parental cells (at their top drug concentrations). For combination resistance, cells were incubated as

Cell Research	<p>above but with alternative dose escalation until a top concentration was acquired (PLX4032 10 <math>\mu\text{mol/L}</math> and GSK1120212 1 <math>\mu\text{mol/L}</math>). Stocks and dilutions of PLX4032, GSK1120212, and SCH772984 were made in DMSO solvent. Cell proliferation experiments were carried out in a 96-well format (six replicates), and cells were plated at a density of 4,000 cells per well. At 24 hours after cell seeding, cells were treated with DMSO or a 9-point IC50 dilution (0.001-10 <math>\mu\text{mol/L}</math>) at a final concentration of 1% DMSO for all concentrations. Viability was assayed 5 days after dosing using the ViaLight luminescence kit following the manufacturer's recommendations (<math>n = 6</math>, mean <math>\pm</math> SE). For the cell line panel viability assay, cells were treated with SCH772984 for 4 days and assayed by the CellTiterGlo luminescent cell viability assay. For IncuCyte analysis, cells were plated as above in 96-well plates, and image-based cell confluence data were collected every 2 hours during live growth. For engineered resistant lines, cells were infected with lentivirus produced from lentiORF constructs expressing either RFP, KRASG13D, BRAFV600E, truncated BRAFV600E lacking exons 2-8 (<math>\Delta 2-8</math>), MEK1P124L, MEK1F129L, or constitutively active MEK1DD (S218D+S222D). Cells were selected in blasticidin (20 <math>\mu\text{g/mL}</math>) and used for ViaLight assays as described above [1].</p>
Animal Research	<p>Nude mice were injected subcutaneously with specific cell lines, grown to approximately 100 <math>\text{mm}^3</math>, randomized to treatment groups (10 mice/group), and treated intraperitoneally with either SCH772984 or vehicle according to the dosing schedule indicated in the figure legends. Tumor length (L), width (W), and height (H) were measured during and after the treatment periods by a caliper twice weekly on each mouse and then used to calculate tumor volume using the formula <math>(L \times W \times H)/2</math>. Animal body weights were measured on the same days twice weekly. Data were expressed as mean <math>\pm</math> SEM. Upon completion of the experiment, vehicle- and SCH772984-treated tumor biopsies were processed for Western blot analysis [1].</p>

### Solubility Information

Solubility	<p>H2O: &lt; 1 mg/mL (insoluble or slightly soluble),            Ethanol: &lt; 1 mg/mL (insoluble or slightly soluble),            DMSO: 16.7 mg/mL (28.42 mM), Sonication is recommended.            (&lt; 1 mg/ml refers to the product slightly soluble or insoluble)</p>
In vivo Formulation	<p>10% DMSO+90% Saline: 0.54 mg/mL (0.92 mM), Solution.  <i>Please add the solvents sequentially, clarifying the solution as much as possible before adding the next one. Dissolve by heating and/or sonication if necessary. Working solution is recommended to be prepared and used immediately. The formulation provided above is for reference purposes only. In vivo formulations may vary and should be modified based on specific experimental conditions.</i></p>

### Preparing Stock Solutions

---

	<b>1mg</b>	<b>5mg</b>	<b>10mg</b>
1 mM	1.7016 mL	8.5082 mL	17.0164 mL
5 mM	0.3403 mL	1.7016 mL	3.4033 mL
10 mM	0.1702 mL	0.8508 mL	1.7016 mL
50 mM	0.034 mL	0.1702 mL	0.3403 mL

---

Please select the appropriate solvent to prepare the stock solution, according to the solubility of the product in different solvents. Please use it as soon as possible.

Note: The dilution table applies only to solid products. For liquid products, please calculate the stock solution based on the stated concentration and/or density.

## Reference

- Wong DJ, et al. Antitumor activity of the ERK inhibitor SCH772984 [corrected] against BRAF mutant, NRAS mutant and wild-type melanoma. *Mol Cancer*. 2014 Aug 20;13:194.
- Wang X, Xie Q, Ji Y, et al. Targeting KRAS-mutant stomach/colorectal tumors by disrupting the ERK2-p53 complex. *Cell Reports*. 2023, 42(1): 111972.
- Caiola E, Iezzi A, Tomanelli M, et al. LKB1 deficiency renders non-small-cell lung cancer cells sensitive to ERK inhibitors.: ERK inhibitors in LKB1 mutated NSCLC[J]. *Journal of Thoracic Oncology*. 2019.
- Yang J, Wang X, Fan Y, et al. Tropoelastin improves adhesion and migration of intra-articular injected infrapatellar fat pad MSCs and reduces osteoarthritis progression. *Bioactive Materials*. 2021
- Zeng F, Li Y, Deng Z, et al. SARS-CoV-2 Spike Spurs Intestinal Inflammation via VEGF Production in Enterocytes. *EMBO Molecular Medicine*. 2022 May 9;14(5):e14844. doi: 10.15252/emmm.202114844. Epub 2022 Apr 19.
- Xie D, Ge X, Ma Y, et al. Clemastine improves hypomyelination in rats with hypoxic-ischemic brain injury by reducing microglia-derived IL-1 $\beta$  via P38 signaling pathway. *Journal of neuroinflammation*. 2020, 17(1): 1-17.
- Bin Y F, Ma N, Lu Y X, et al. Erythromycin reverses cigarette smoke extract-induced corticosteroid insensitivity by inhibition of the JNK/c-Jun pathway. *Free Radical Biology and Medicine*. 2020, 152: 494-503
- Chang G, Xiao W, Xu Z, et al. Pterostilbene Induces Cell Apoptosis and Cell Cycle Arrest in T-Cell Leukemia/Lymphoma by Suppressing the ERK1/2 Pathway. *BioMed Research International*. 2017;2017:9872073
- Zhu F D, Wang B D, Qin D L, et al. Carpesii fructus extract exhibits neuroprotective effects in cellular and Caenorhabditis elegans models of Parkinson's disease. *CNS Neuroscience & Therapeutics*. 2023
- Zheng M, Zhai Y, Yu Y, et al. TNF compromises intestinal bile-acid tolerance dictating colitis progression and limited infliximab response. *Cell Metabolism*. 2024
- Bian Y, Shan G, Bi G, et al. Targeting ALDH1A1 to enhance the efficacy of KRAS-targeted therapy through ferroptosis. *Redox Biology*. 2024: 103361.
- Lai J, Li Y, Ran M, et al. Xanthotoxin, a novel inducer of platelet formation, promotes thrombocytopoiesis via IL-1R1 and MEK/ERK signaling. *Biomedicine & Pharmacotherapy*. 2023, 163: 114811.
- Morris EJ, et al. Discovery of a novel ERK inhibitor with activity in models of acquired resistance to BRAF and MEK inhibitors. *Cancer Discov*. 2013 Jul;3(7):742-50.
- Li M, Wang Z, Fu S, et al. Taurine reduction of injury from neutrophil infiltration ameliorates Streptococcus uberis-induced mastitis. *International Immunopharmacology*. 2023, 124: 111028.
- Jiang S, Wang Z, Zhu T, et al. The Downregulation of EIF3a Contributes to Vemurafenib Resistance in Melanoma By Activating ERK Via PPP2R1B[J]. 2021
- Lang J Y, Wang X, Xie Q, et al. Targeting KRAS-mutant stomach/colorectal tumours by disrupting the ERK2-p53 complex[J]. *bioRxiv*. 2020
- Jiang S, Wang Z, Zhu T, et al. The Downregulation of EIF3a Contributes to Vemurafenib Resistance in Melanoma By Activating ERK Via PPP2R1B. *Frontiers in Pharmacology*. 2021: 2242.
- Zhang B, Zhao J, Wang Z, et al. DL0410 attenuates oxidative stress and neuroinflammation via BDNF/TrkB/ERK/CREB and Nrf2/HO-1 activation. *International Immunopharmacology*. 2020, 86: 106729.
- Chang G, Xiao W, Xu Z, et al. Pterostilbene Induces Cell Apoptosis and Cell Cycle Arrest in T-Cell Leukemia/Lymphoma by Suppressing the ERK1/2 Pathway[J]. *BioMed Research International*. 2017;2017:9872073
- Zhang B, Zhao J, Wang Z, et al. DL0410 attenuates oxidative stress and neuroinflammation via BDNF/TrkB/ERK/CREB and Nrf2/HO-1 activation[J]. *International Immunopharmacology*. 2020, 86: 106729.
- Zhao Z, Xue F, Gu Y, et al. Crosstalk between the muscular estrogen receptor  $\alpha$  and BDNF/TrkB signaling alleviates metabolic syndrome via 7, 8-dihydroxyflavone in female mice. *Molecular Metabolism*. 2020: 101149.
- Bin Y F, Ma N, Lu Y X, et al. Erythromycin reverses cigarette smoke extract-induced corticosteroid insensitivity by inhibition of the JNK/c-Jun pathway[J]. *Free Radical Biology and Medicine*. 2020, 152: 494-503.
- Caiola E, Iezzi A, Tomanelli M, et al. LKB1 Deficiency Renders NSCLC Cells Sensitive to ERK Inhibitors. *Journal of Thoracic Oncology*. 2020, 15(3): 360-370
- Xie D, Ge X, Ma Y, et al. Clemastine improves hypomyelination in rats with hypoxic-ischemic brain injury by reducing microglia-derived IL-1 $\beta$  via P38 signaling pathway[J]. *Journal of neuroinflammation*. 2020, 17(1): 1-17.
- Caiola E, Iezzi A, Tomanelli M, et al. LKB1 deficiency renders non-small-cell lung cancer cells sensitive to ERK inhibitors.: ERK inhibitors in LKB1 mutated NSCLC. *Journal of Thoracic Oncology*. 2019
- Zhao Z, Xue F, Gu Y, et al. Crosstalk between the muscular estrogen receptor  $\alpha$  and BDNF/TrkB signaling alleviates

metabolic syndrome via 7, 8-dihydroxyflavone in female mice[J]. Molecular Metabolism. 2020: 101149.  
Chang Y W, Wang C C, Yin C F, et al. Quantitative phosphoproteomics reveals ectopic ATP synthase on mesenchymal stem cells to promote tumor progression via ERK/c-Fos pathway activation. Molecular & Cellular Proteomics. 2022, 21(6)

**Inhibitor · Natural Compounds · Compound Libraries · Recombinant Proteins**

This product is for Research Use Only · Not for Human or Veterinary or Therapeutic Use

Tel:781-999-4286 E\_mail:info@targetmol.com Address:34 Washington Street,Wellesley Hills,MA 02481